High CBX3 expression was a biomarker of poor prognosis for HCC patients. (a, b) Kaplan‑Meier analysis showed that overexpression of CBX3 was correlated with poor overall survival (OS, A) and progression-free survival (PFS, B) of HCC patients based on analysis of TCGA LIHC database. (c, d) Regardless of the TNM stage (TNM I–II or TNM III–IV), HCC patients with high expression of CBX3 had both a short OS (c) and a short PFS (d).